Olivera J. Finn and Robert E. Schoen/Invest in America's health Pittsburgh Post Gazette And because MUC1 is abnormally produced in other cancers, including pancreatic, breast, lung, prostate and ovarian, we plan to test the vaccine in patients who have premalignant lesions leading to those cancers, too. ... in NIH is the foundation for ... |
